Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts

By D. Baim, D. Wahr, B. George, M. Leon, Joel D Greenberg, D. Cutlip, Unsal Kaya, J. Popma, K. Ho, R. Kuntz. Circulation, 2002

700 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Guidelines on myocardial revascularization. (2010, methodology): “less than with native vessel PCI [171].”
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. (2005, methodology): “It was investigated in the SAFER trial in patients having PCI of a SVG.(346) The primary endpoint [death, MI, emergency bypass, or target lesion revascularization (TLR) by 30 days] was significantly reduced from 16.”
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention (2006, background): “(Level of Evidence: B) Published clinical trials using distal embolic protection devices confirm their benefit in improving cardiovascular outcomes among patients undergoing PCI to saphenous vein grafts (65,66).”